Clinical trial
A Multi-Center, Randomized, Controlled, Two-Arm, Pivotal Phase III Study to Evaluate the Safety and Efficacy of MK-3475 Compared to Ipilimumab in Patients with Advanced Melanoma
To evaluate the overall survival (OS) in patients with advanced MEL receiving either MK-3475 or IPI.
| Category | Value |
|---|---|
| Study start date | 2013-01-18 |